IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Erasca, Inc.
Nouscom SRL
Werewolf Therapeutics, Inc.
Hoffmann-La Roche
University of California, San Diego
M.D. Anderson Cancer Center
Centre Leon Berard
Novartis
Inhibrx Biosciences, Inc
Amgen
University of California, San Diego
Mirati Therapeutics Inc.
BioAtla, Inc.
DEKA Biosciences
Merck Sharp & Dohme LLC
Duke University
Carisma Therapeutics Inc
Lyvgen Biopharma Holdings Limited
Salubris Biotherapeutics Inc
ENB Therapeutics, Inc
MedImmune LLC
Mural Oncology, Inc